Regeneron Pharmaceuticals Inc. will develop its cemiplimab in combination with ISA Pharmaceuticals BV's ISA101 for cervical and head-and-neck cancer under a new agreement.
As part of the deal, Regeneron will make an upfront payment and an equity investment in exchange for an option to an exclusive, global license for ISA101. Upon exercising the exclusivity option for ISA101, ISA may receive milestone payments and tiered royalty payments contingent on regulatory approvals, sales and additional indications. Further financial details were not disclosed.
The companies will jointly fund and conduct the clinical trials.
Cemiplimab, also known as REGN2810, is a PD-1 antibody being jointly developed by Regeneron and Sanofi. The medicine is being studied as a single therapy in multiple tumor types including skin, lung and cervical cancers, and in other therapeutic combinations.
